Known as Tecartus in the US, this is the third CAR-T therapy to be recommended for approval in Europe and will be the first for MCL, an aggressive form of non-Hodgkin’s lymphoma (NHL).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback